Attorneys General File Federal Lawsuit Challenging FDA Restrictions On Abortion Drug

SG
Shipman & Goodwin LLP

Contributor

Shipman & Goodwin’s value lies in our commitment -- to our clients, to the profession and to the community. We have one goal: to help our clients achieve their goals. How we accomplish it is simple: we devote our considerable experience and depth of knowledge to understand each client’s unique needs, business and industry, and then we develop solutions to meet those needs. Clients turn to us when they need a trusted advisor. With our invaluable awareness of each client’s challenges, we can counsel them at every step -- to keep their operations running smoothly, help them navigate complex business transactions, position them for future growth, or resolve business disputes. The success of our clients is of primary importance to us and our attorneys invest meaningful time getting to know the client's business and are skilled in the practice areas and industry sectors critical to that success. With more than 175 attorneys in offices throughout Connecticut, New York and in Washington, DC, we serve the needs of
On February 23, 2023, Washington State Attorney General, Bob Ferguson, joined by Attorneys General from Nevada, Delaware, Arizona, Illinois, Connecticut, Colorado...
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

On February 23, 2023, Washington State Attorney General, Bob Ferguson, joined by Attorneys General from Nevada, Delaware, Arizona, Illinois, Connecticut, Colorado, Vermont, New Mexico, Michigan and Rhode Island, filed a federal lawsuit challenging the restrictions placed by the FDA on Mifepristone on the basis that such restrictions are overly burdensome and not based upon medical science.

Attorney General Ferguson also filed a preliminary injunction asking the court to halt the enforcement of the FDA's restriction on Mifepristone while the case proceeds. In particular, the suit claims that the FDA's restrictions expose patients and providers to potential abuse, harassment and violence by having to submit burdensome certifications and other documents that would be accessible in the patient's medical record and accessible by providers in states where abortion is illegal. [https://agportal-s3bucket.s3.amazonaws.com/uploadedfiles/Another/News/Press_Releases/Mifepristone%20Complaint.pdf.]

As previously reported on the Dobbs Resource page, a suit is pending in a Texas federal court challenging the FDA's loosening of the restrictions on the procurement of Mifepristone. Commentators have argued that if there is a split decision by these two federal courts, an appeal to the Supreme Court is likely.

As new developments arise, we will continue to update our Dobbs Decision Resource Center. In the meantime, please contact one of the lawyers in Shipman's Health Law practice group if you have questions about this ever-changing legal landscape.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Attorneys General File Federal Lawsuit Challenging FDA Restrictions On Abortion Drug

United States Food, Drugs, Healthcare, Life Sciences

Contributor

Shipman & Goodwin’s value lies in our commitment -- to our clients, to the profession and to the community. We have one goal: to help our clients achieve their goals. How we accomplish it is simple: we devote our considerable experience and depth of knowledge to understand each client’s unique needs, business and industry, and then we develop solutions to meet those needs. Clients turn to us when they need a trusted advisor. With our invaluable awareness of each client’s challenges, we can counsel them at every step -- to keep their operations running smoothly, help them navigate complex business transactions, position them for future growth, or resolve business disputes. The success of our clients is of primary importance to us and our attorneys invest meaningful time getting to know the client's business and are skilled in the practice areas and industry sectors critical to that success. With more than 175 attorneys in offices throughout Connecticut, New York and in Washington, DC, we serve the needs of
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More